Premium
P3–088: 30 months prospective study on plasma amyloid beta protein 42, medial temporal lobe atrophy and change of cognition in the VITA cohort
Author(s) -
Blasko Imrich,
Jellinger Kurt,
Kemmler Georg,
Krampla Wolfgang,
Jungwirth Susanne,
Wichart Ildigo,
Heinz Tragl Karl,
Fischer Peter
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1355
Subject(s) - cognition , atrophy , cognitive decline , neuropsychology , effects of sleep deprivation on cognitive performance , medicine , psychology , temporal lobe , cohort , gerontology , prospective cohort study , disease , cardiology , audiology , dementia , neuroscience , epilepsy
Also, to determine whether levels of ACE2 are altered in subjects with AD as compared to control subjects. Methods: 110 patients with probable AD and 220 non-demented controls underwent clinical and neuropsychological examination and had blood samples taken for plasma peptidase measurement and genotyping. Plasma ACE and ACE2 levels were measured using fluorogenic assays. Samples were genotyped for the ACE I/D polymorphism and apolipoprotein E. Results: After adjustment for ACE inhibitor medication, ACE I/D genotype, age and sex, ACE levels were significantly decreased in the AD group compared to controls. A significant association was detected between ACE I/D genotype and ACE level in the control group but not the case group. There was no significant correlation between MMSE score and plasma ACE level in the AD group. There was no significant difference between the two groups with regards to plasma ACE2 level. Conclusions: Our preliminary data shows a decreased plasma ACE level in AD. Follow-up of this cohort over a two year period with serial plasma ACE measurements should further elaborate on these results.